Low Lung Volumes: Causes, Symptoms, and Treatment Options

Low lung volumes mean your lungs hold less air than expected for someone of your age, height, sex, and ethnicity. The hallmark measurement is total lung capacity (TLC) falling below the lower limit of normal, which is the defining feature of what clinicians call restrictive lung disease. The causes span from scarring deep inside the lung tissue to problems that have nothing to do with the lungs themselves, like weak breathing muscles or excess weight compressing the chest. Because the label covers such different conditions, the symptoms, outlook, and treatment vary enormously depending on what is actually driving the restriction.

How Low Lung Volumes Are Detected

Spirometry is the most common first step. You blow hard and fast into a mouthpiece, and the machine records how much air you can exhale and how quickly. When both your total exhaled volume and airflow speed are reduced proportionally, the pattern raises suspicion for a restrictive problem. But spirometry alone can’t confirm it. The gold standard for diagnosing truly low lung volumes is measuring total lung capacity directly, and that usually requires body plethysmography, sometimes called the “body box.” You sit inside a sealed, phone-booth-sized chamber and breathe against a closed shutter while sensors track pressure changes to calculate how much air your lungs contain at rest and at full inflation.

Body plethysmography measures functional residual capacity first, then derives total lung capacity and residual volume from deep breathing maneuvers.¹ Total lung capacity below the lower limit of normal is what clinches the diagnosis of a restrictive pattern.² An older alternative, the helium dilution technique, works by having you rebreathe a known concentration of helium while a gas analyzer tracks how much the helium gets diluted by the air already in your lungs. In people with restrictive disease the two methods tend to agree, but in obstructive disease helium dilution can underestimate lung volume while plethysmography tends to be more accurate.³

It is worth knowing that a restrictive-looking spirometry pattern does not always mean lung volumes are truly low. Some people produce a pattern that mimics restriction on spirometry but turn out to have normal total lung capacity when it is measured directly. That is why guidelines stress using plethysmography or dilution techniques to confirm the diagnosis rather than relying on spirometry alone.⁴

Causes That Start Inside the Lungs

When the problem originates in the lung tissue itself, the usual culprit is something stiffening or destroying the delicate architecture of the air sacs. The most well-known example is idiopathic pulmonary fibrosis (IPF), a progressive scarring disease where the flexible elastic tissue of the lung gets replaced by thick, collagen-rich scar tissue.⁵ As more of the lung stiffens, compliance drops, meaning the lung resists being stretched open. Reduced compliance tracks closely with how much scarring is present on biopsy.⁶ The result is a lung that simply cannot inflate to its former size, so all the volume measurements shrink.

IPF also disrupts gas exchange, reduces the lung’s diffusing capacity for oxygen and carbon dioxide, and increases dead-space ventilation, the fraction of each breath that doesn’t participate in gas exchange.⁷ Other forms of interstitial lung disease, such as hypersensitivity pneumonitis from inhaled allergens, sarcoidosis, and lung involvement in connective tissue diseases like scleroderma or rheumatoid arthritis, produce similar volume loss through inflammation and scarring, though the pattern and pace vary.

Acute respiratory distress syndrome (ARDS) is a different mechanism but lands in the same territory. In ARDS, widespread inflammation makes the tiny blood vessels in the lung leak fluid into the air sacs. The flooded and collapsed regions can no longer participate in breathing, compliance plummets, and effective lung volume drops sharply.⁸ Unlike fibrosis, ARDS can be reversible if the underlying trigger, whether pneumonia, sepsis, or aspiration, is treated in time.

Lung surgery is another straightforward cause. Removing a lobe reduces total capacity by roughly the volume of the tissue that was taken out, though some compensatory expansion of the remaining lobes occurs over the following year.⁹

Causes That Start Outside the Lungs

The lungs themselves can be perfectly healthy and still end up with low volumes if something prevents them from expanding. Three broad categories account for most of these cases: chest wall abnormalities, neuromuscular weakness, and obesity.

Severe scoliosis is the classic chest wall culprit. When the spinal curve exceeds roughly 70 degrees, or involves seven or more vertebrae, or sits high in the thoracic spine, the ribcage deforms enough to physically compress the lungs and restrict their growth.¹⁰ The total lung capacity drops in proportion to the severity of the deformity, and the loss is multifactorial, driven by rib crowding, loss of normal curvature, and mechanical disadvantage of the breathing muscles.

Neuromuscular diseases affect lung volumes by weakening the muscles that inflate the chest. The diaphragm does most of the work during quiet breathing, and in conditions like Pompe disease, various myopathies, and motor neuron diseases, diaphragmatic motion becomes measurably impaired. MRI studies show that in myopathy patients, the diaphragm moves less relative to the chest wall than in healthy people, and its curvature paradoxically increases during inspiration rather than flattening, reflecting insufficient contraction.¹¹ A practical bedside clue is a large drop in vital capacity when someone lies down compared to sitting up, since gravity pulls the abdominal contents onto a weak diaphragm.¹²

Obesity is probably the most common extrapulmonary cause of reduced lung volumes in the general population, and it is under-recognized. Adipose tissue around the ribcage and in the abdominal cavity loads the chest wall and pushes up on the diaphragm, reducing functional residual capacity (FRC).¹³ The relationship between body mass index and FRC is exponential rather than linear: as BMI rises, FRC and expiratory reserve volume fall steeply, and people with morbid obesity may end up breathing near their residual volume, the point where very little air moves in and out with each breath.¹⁴ Unlike fibrosis, this form of restriction is at least partly reversible with weight loss.

What Low Lung Volumes Feel Like

The dominant symptom is breathlessness, especially during physical activity. But the way people breathe when their lung volumes are low has a characteristic signature. Compared to healthy individuals, people with restrictive lung disease breathe faster and take shallower breaths. Their respiratory rate is elevated, and each inspiration often lasts a second or less.¹⁵ The brain’s respiratory center ramps up its drive to compensate for the smaller tidal volume, which shows up on testing as a higher mean inspiratory flow.

This rapid, shallow pattern isn’t just a quirk. Research on interstitial lung disease found that it closely mimics the breathing pattern you would see if you strapped an elastic load around a healthy person’s chest. The stiffer the lungs, the faster and shallower the breathing, suggesting that stretch receptors in the lung tissue feed back to the brain and adjust the pattern automatically.¹⁶ This explains why many people with low lung volumes feel winded during conversation or mild exertion even though their oxygen levels might still be acceptable at rest.

Beyond breathlessness, a persistent dry cough is common in fibrotic lung diseases. Fatigue, chest tightness, and difficulty sleeping, particularly lying flat, round out the typical complaints. In neuromuscular causes, morning headaches from overnight carbon dioxide buildup can be an early warning sign.

Imaging and the Diagnostic Workup

Lung function testing tells you that volumes are low, but it doesn’t tell you why. That’s where imaging comes in. High-resolution CT (HRCT) of the chest has become indispensable for sorting out the underlying cause, especially when interstitial lung disease is suspected. HRCT can identify the specific scarring patterns, ground-glass opacities, or honeycombing that point toward a particular diagnosis, and it is far more sensitive than a standard chest X-ray.

In one study of patients with progressive systemic sclerosis, HRCT detected interstitial disease in over 90% of patients, while chest X-rays showed definite abnormalities in only about 40%. Over a third of the patients had completely normal chest X-rays despite having interstitial lung involvement visible on CT.¹⁷ For IPF specifically, HRCT can often provide a confident diagnosis without the need for a surgical lung biopsy.¹⁸

Serial HRCT scans also play a role after diagnosis. Repeat imaging can reveal disease progression, treatment response, or new complications that lung function tests alone would miss.¹⁹ When the cause isn’t in the lungs, imaging shifts focus: an upright and supine chest film or fluoroscopy can reveal a paralyzed or elevated diaphragm, and spinal imaging characterizes scoliosis. The diagnostic path depends on the clinical picture, but imaging almost always adds information that pulmonary function testing cannot.

Treatment for Fibrotic Lung Disease

When low lung volumes are caused by progressive fibrosis, particularly IPF, the main pharmacological options are the antifibrotic drugs pirfenidone and nintedanib. These medications do not reverse existing scarring, but they slow the rate at which lung function declines. In the CAPACITY trial, pirfenidone reduced the average decline in forced vital capacity from about 12% to about 8% over 72 weeks, and roughly halved the proportion of patients experiencing a decline of 10% or more.²⁰

Staying on antifibrotic therapy matters even after lung function has already started to drop. A multicenter study found that patients who stopped their antifibrotic after an initial decline in forced vital capacity experienced substantially greater additional decline and higher odds of further progression, transplant, or death compared to those who continued treatment.²¹ The takeaway is that these drugs buy time, and stopping them prematurely can erase that benefit.

Pulmonary Rehabilitation

Pulmonary rehabilitation, a structured program of exercise training, breathing techniques, and education, is typically associated with chronic obstructive lung disease but is just as valuable for restrictive conditions. In one study of patients with restrictive lung disease, exercise endurance on a treadmill improved by roughly ten minutes after eight weeks and the improvement persisted at one year.²² Rehabilitation doesn’t increase your total lung capacity. What it does is train your muscles, your cardiovascular system, and your breathing efficiency to get more out of the capacity you have.

Even home-based programs can deliver meaningful results. A six-month home rehabilitation program that combined breathing retraining, walking, and respiratory muscle exercises improved both inspiratory and expiratory muscle strength, six-minute walking distance, and quality-of-life scores in patients with restrictive lung disease, with improvements comparable to those seen in patients with obstructive disease doing the same program.²³ That last point is important because many patients with restrictive disease are told that rehab “isn’t for them,” when the evidence says otherwise.

Noninvasive Ventilation and Lung Transplantation

For people whose low lung volumes come from chest wall deformities or neuromuscular weakness, noninvasive ventilation (NIV) can be transformative. A bilevel positive-pressure device, essentially a more sophisticated version of a CPAP machine, pushes air into the lungs through a nasal or face mask, helping inflate them more fully than the weakened muscles can manage alone. Peak pressures of about 20 to 25 cmH₂O are commonly needed, and a nasal mask is generally preferred.²⁴ Many patients use NIV only at night, targeting the nocturnal hypoventilation that causes morning headaches and fatigue. In progressive neuromuscular disease, NIV can delay respiratory failure and improve survival.

When fibrotic or other interstitial lung diseases progress to the point where medications and supportive care are no longer enough, lung transplantation becomes the remaining life-extending option. Transplant is considered for advanced IPF, fibrotic hypersensitivity pneumonitis, sarcoidosis, and connective tissue disease-associated interstitial lung disease.²⁵ Patients with connective tissue diseases were once considered poor candidates because of concerns about the underlying autoimmune condition, but recent evidence suggests their survival after transplant is comparable to that of patients transplanted for other end-stage lung diseases.²⁶

One practical complication in transplantation for restrictive disease is size matching. People whose lungs have been shrunken for years often have small thoracic cavities, and a standard-sized donor lung may be too large to fit comfortably. Surgical volume reduction of the graft can address this when oversized donor lungs are the best available option.²⁷

When Low Lung Volumes Affect the Heart

Chronic lung disease doesn’t just damage the lungs; it can strain the right side of the heart. When large portions of the lung are scarred or collapsed, the blood vessels running through those areas narrow or are destroyed. The right ventricle, which pumps blood into the lungs, has to work harder against the increased resistance. Over time, this leads to pulmonary hypertension and eventually right ventricular dysfunction, a condition historically called cor pulmonale.²⁸ Symptoms of right heart strain include swollen ankles, fluid retention, and worsening exercise intolerance beyond what the lung disease alone would explain. Screening for pulmonary hypertension with echocardiography is a routine part of managing advanced restrictive lung disease for this reason.

Pregnancy and Other Temporary Causes

Not all low lung volumes signal disease. Pregnancy is the most common situation where functional residual capacity drops in a healthy person. As the uterus expands and the diaphragm rides higher, FRC decreases, especially in the third trimester. At the same time, hormonal changes driven by progesterone and relaxin loosen the ribcage ligaments and increase inspiratory capacity, so total lung capacity stays roughly preserved even though the resting position of the lungs shifts upward.²⁹ The result is that many pregnant people feel short of breath, particularly when sitting or lying down, but their ability to take a deep breath is actually maintained or even slightly enhanced. These changes reverse after delivery.

Large pleural effusions, where fluid accumulates between the lung and the chest wall, are another reversible cause. The fluid compresses the lung from the outside, and draining it restores volume immediately. Ascites, fluid in the abdominal cavity, can push up the diaphragm in a way that mimics obesity-related restriction. Recognizing these temporary and treatable causes matters because the management is completely different from treating fibrosis or neuromuscular weakness.

Living with Low Lung Volumes

The psychological burden of chronic restrictive lung disease is substantial and often underappreciated. In a study of patients with interstitial lung disease, roughly four out of five reported some degree of anxiety or depression, ranging from mild to extreme emotional distress.³⁰ Beyond breathlessness and cough, patients frequently report fear about disease progression, social isolation from reduced mobility, and frustration with the unpredictability of their symptoms.³¹

Quality-of-life assessments tend to focus on respiratory complaints, but the non-respiratory symptoms often matter just as much to the people living with the disease. Loss of independence in daily activities, difficulty maintaining employment, and strain on relationships are consistently cited concerns. Palliative care, which focuses on symptom management and emotional support regardless of disease stage, is increasingly recognized as a component of comprehensive care for advanced restrictive lung disease, not just something reserved for the final weeks of life. Integrating it earlier in the disease course can address the symptoms that lung function numbers alone never capture.

How Spirometry Became the Standard

The ability to measure lung volumes has a surprisingly long history. The spirometer was introduced in 1846 by John Hutchinson, who coined both the term “spirometer” and “vital capacity.”³² Measurements of vital capacity had actually been made even earlier, in the 18th century, and by the mid-1800s large numbers of healthy people and patients with tuberculosis had been tested. Yet the clinical world was slow to adopt the technology. Vital capacity saw little routine clinical use until the second half of the 20th century, and the forced expiratory volume in one second, now the most widely reported spirometry value, was first described only about 70 years ago.³³ The tools we now rely on to diagnose low lung volumes were available for over a century before medicine figured out how to use them systematically, a reminder that measurement alone is not enough without the interpretive framework to make it meaningful.